Cargando…

Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients

BACKGROUND: Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is not a review focusing on all real-life experience with belimumab to date that could help to describe how this drug behaves in the Spanish clinical setting. OBJECTIVE: To describe the charact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escalera, Carlos Rodríguez, Guisado, Ángela María Zurita, Mateo, Francisco Javier, Bahamontes-Rosa, Noemí, Villanueva, María Jesús García
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308486/ https://www.ncbi.nlm.nih.gov/pubmed/35871173 http://dx.doi.org/10.1007/s10067-022-06287-9

Ejemplares similares

B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
por: Hunnicutt, Jacob N, et al.
Publicado: (2022)

Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
por: D'Cruz, David, et al.
Publicado: (2023)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
por: Cevey, Maria, et al.
Publicado: (2019)

PReS-FINAL-2285: Pediatric non-renal SLE presenting as periorbital edema: response to treatment with belimumab
por: Arabshahi, B
Publicado: (2013)

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
por: Bruce, I N, et al.
Publicado: (2016)

Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review
por: Huang, Shirley P., et al.
Publicado: (2022)

Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies
por: Trentin, Francesca, et al.
Publicado: (2018)

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE
por: Struemper, Herbert, et al.
Publicado: (2022)

Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study
por: Sun, Fangfang, et al.
Publicado: (2023)

Efficacy and Safety of Belimumab in Lupus Nephritis Patients: A Real-World Observational Study in China
por: Tan, Meng, et al.
Publicado: (2023)

Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies
por: Trentin, Francesca, et al.
Publicado: (2018)

Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry
por: Juliao, Patricia, et al.
Publicado: (2022)

Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis
por: Birt, Julie A, et al.
Publicado: (2020)

Real life experience on the effect of Belimumab in patients with active systemic lupus
por: Scheinberg, Morton, et al.
Publicado: (2014)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
por: Gomez, Alvaro, et al.
Publicado: (2023)

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study
por: Bae, Sang-Cheol, et al.
Publicado: (2022)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
por: Collins, Christopher E., et al.
Publicado: (2020)

Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study
por: Wang, Dahai, et al.
Publicado: (2022)

Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study
por: Bell, Christopher F., et al.
Publicado: (2023)

A novel validated assay to support the discovery of new anti-malarial gametocytocidal agents
por: Bahamontes-Rosa, Noemí, et al.
Publicado: (2016)

Poor immunogenicity upon SARS-CoV-2 mRNA vaccinations in autoimmune SLE patients is associated with pronounced EF-mediated responses and anti-BAFF/Belimumab treatment
por: Faliti, Caterina E., et al.
Publicado: (2023)

First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study
por: Schwarting, Andreas, et al.
Publicado: (2016)

Evaluating the Use of Glucocorticoids Among Belimumab‐Treated Patients With Systemic Lupus Erythematosus in Real‐World Settings Using the Rheumatology Informatics System for Effectiveness Registry
por: Hammam, Nevin, et al.
Publicado: (2022)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Clinical response to belimumab in academic clinical practices
por: Reddy, Arthi, et al.
Publicado: (2014)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)
por: Zen, Margherita, et al.
Publicado: (2023)

Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study
por: Pericay, Carles, et al.
Publicado: (2023)

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
por: Santos, José Ramón, et al.
Publicado: (2023)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA
por: Bell, Christopher F, et al.
Publicado: (2020)

New treatment options for lupus – a focus on belimumab
por: Chiche, Laurent, et al.
Publicado: (2012)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m3muqnr89gaasdo20g93rsgdqj